Author's response to reviews

Title: ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel

Authors:

LF Wang (baxia1108@126.com)
J Wei (weijia01627@hotmail.com)
XP Qian (qianxiaoping210@hotmail.com)
HT Yin (yinhaitao21001@hotmail.com)
Y Zhao (zhao_yang@njmu.edu.cn)
LX Yu (njyulixa@hotmail.com)
TT Wang (tingting_only@126.com)
BR Liu (baoruiliu@nju.edu.cn)

Version: 3 Date: 13 March 2008

Author's response to reviews: see over
Dear Dr. J. A. Le Good:

Thanks you very much for your time and effort on this manuscript. We have revised manuscript in light of the reviewer 1 comments, as noted below:

1. **Our Feedback:** The original question has been answered, except in one minor point: Even if the assay has been described in a previous article, it could be a good idea to explain also in this paper if the initial number of tumor cells raises or drops after 7 days in serum-free medium, since it could alter the sensitivity of the cells to cisplatin and docetaxel.

   **Reply:** We made additional explanation on question of tumor cells raises or drops in paragraph 1of results part, page 6.

2. **Our feedback:** In my opinion, the authors should say in the text (p7) that the correlation BRCA/cisplatin is due to the two extreme points, and that a higher number of samples would be necessary to confirm it.

   **Reply:** We have modified manuscript according to the reviewer’s valuable suggestion.